|Bid||0.00 x 1300|
|Ask||0.00 x 1800|
|Day's range||10.20 - 10.91|
|52-week range||7.61 - 19.99|
|Beta (5Y monthly)||2.51|
|PE ratio (TTM)||N/A|
|Earnings date||03 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||17.45|
BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BioCryst Pharmaceuticals (NASDAQ: BCRX) stock defied the market's gravity on Wednesday by rising incrementally. Although it was a challenging day for stocks in general, with the S&P 500 index sinking by over 1%, BioCryst landed in the black thanks to some encouraging regulatory news. Before market open, BioCryst announced that the Food and Drug Administration (FDA) has granted its BCX9250 investigational drug fast-track designation.
The biotech whiffs on both revenue and profitability for its first quarter, and indicates more losses are in store.